Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2018 / Article
Special Issue

Mitochondrial Bioenergetics and Quality Control Mechanisms in Health and Disease

View this Special Issue

Research Article | Open Access

Volume 2018 |Article ID 3175313 | 12 pages | https://doi.org/10.1155/2018/3175313

Increased Mitochondrial Protein Levels and Bioenergetics in the Musculus Rectus Femoris of Wfs1-Deficient Mice

Academic Editor: Julio C. B. Ferreira
Received14 Jun 2018
Revised15 Aug 2018
Accepted25 Sep 2018
Published21 Nov 2018

Abstract

Wfs1 deficiency leads to a progressive loss of plasma insulin concentration, which should reduce the consumption of glucose in insulin-dependent tissues, causing a variety of changes in intracellular energy metabolism. Our objective here was to assess the changes in the amount and function of mitochondrial proteins in different muscles of Wfs1-deficient mice. Mitochondrial functions were assayed by high-resolution oxygraphy of permeabilized muscle fibers; the protein amount was evaluated by liquid chromatography tandem mass spectrometry (LC/MS/MS) analysis and mRNA levels of the uncoupler proteins UCP2 and UCP3 by real-time PCR; and citrate synthase (CS) activity was determined spectrophotometrically in muscle homogenates. Compared to controls, there were no changes in proton leak and citrate synthase activity in the heart and m. soleus tissues of Wfs1-deficient mice, but significantly higher levels of both of these factors were observed in the m. rectus femoris; mitochondrial proteins and mRNA of UCP2 were also higher in the m. rectus femoris. ADP-stimulated state 3 respiration was lower in the m. soleus, remained unchanged in the heart, and was higher in the m. rectus femoris. The mitochondrial protein amount and activity are higher in Wfs1-deficient mice, as are mitochondrial proton leak and oxygen consumption in m. rectus femoris. These changes in muscle metabolism may be important for identifying the mechanisms responsible for Wolfram syndrome and diabetes.

1. Introduction

Wolframin, which is encoded by the WFS1 gene, is a transmembrane glycoprotein found primarily in the endoplasmic reticulum (ER) and is ubiquitously expressed at high levels in the brain, pancreas, and heart but also has been observed in the liver, spleen, skeletal muscles, and kidney [1, 2]. Deficiency of wolframin induces ER stress and calcium depletion in cells [3, 4], which eventually may lead to the development of Wolfram syndrome type 1 (WS), a complex disease associated with diabetes insipidus, diabetes mellitus, optic atrophy, and deafness [5]. Short stature is also quite common in patients with WS [68], and people with WS often suffer from chronic and progressively increasing fatigue [9], as well as muscle spasms, which are common in most patients and can be very serious [10, 11].

The development of diabetes has been associated with increased ER stress and apoptosis in pancreatic beta cells, leading to insufficient insulin secretion [3, 12]. Wolfram syndrome-related diabetes (WSD) usually develops in childhood [13, 14] and tends to occur earlier than type 1 diabetes (5.4 vs. 7.9 years of age, respectively, ) [15]. Normally, approximately three-quarters of the total body glucose uptake stimulated by insulin is mediated by the skeletal muscles [1618], and therefore, deficit of insulin or resistance of muscle fibers to insulin in diabetes mellitus causes changes in muscle energy metabolism. Diabetic patients may experience muscular weakness in the ankles and knees [19]. Hand-grip strength values were also found to be lower in diabetes patients than in age-matched control subjects [20, 21]. Muscle weakness is related to signs and severity of polyneuropathy (PN), a frequent complication for people with diabetes. In addition to PN, diabetes often leads to lower strength per unit of striated muscle and to the slowing of movements [22]. Accumulation of glycation end products may also be a cause of impaired muscle function in these patients [23].

Previous research has suggested a possible link between WS and mitochondrial DNA mutations [24], and patients with Wolfram syndrome have also been described as having heteroplasmic deletions of mtDNA in skeletal muscles [25, 26]. However, mitochondrial functioning has been poorly studied, with conflicting results [25, 27, 28]. Studies of muscle metabolism and mitochondrial function are limited by the small number of WS patients and a degree of randomness in the collection of biopsies from heterogeneous human muscles; in addition, it is also extremely difficult to analyze changes in different types of human muscle.

Several Wfs1-deficient mice models have been bred in order to study WS [3, 12, 29]. The mouse model we created exhibits a more severe phenotype than mutant mice developed by other labs and as such is a more precise model for the study of WS [30]. As Wfs1 deficiency leads to a progressive loss of β-cells in the pancreas and lower concentrations of plasma insulin [29, 30], our mouse model can also be used to study the mechanisms responsible for type 1 diabetes. Our objective here was to assess changes in mitochondrial function and in the amounts and enzymatic activities of mitochondrial and glycolytic pathway proteins in muscles of Wfs1-deficient mice.

2. Materials and Methods

2.1. Animals

Wfs1-deficient (Wfs1KO) mice were generated as described previously [29, 31]. Experiments were performed with 9–12-month-old Wfs1KO male mice with a 129S6/SvEvTac background and their wild-type littermates. The animals were housed under standard laboratory conditions and kept on a 12 h light–dark cycle (lights on at 07:00) and were given free access to food and water. All experiments in this study involving animals were performed in accordance with the European Parliament Directive 2010/63/EU and under permit (no. 86, May 4, 2016) from the Estonian National Board of Animal Experiments.

2.2. Chemicals and Reagents

K-Lactobionate, ethylene glycol-bis(β-aminoethyl ether)-N,N,N,N-tetraacetic acid (EGTA), and taurine were obtained from Fluka (Buchs, Switzerland); reduced nicotinamide adenine dinucleotide (NADH), pyruvate, and saponin were obtained from SERVA (Heidelberg, Germany); MgCl2 and KCl were obtained from ACROS (Geel, Belgium); and leupeptin was obtained from Roche (Basel, Switzerland). All other reagents, ADP, ATP, bovine serum albumin, enzymes (glucose-6-phosphate dehydrogenase and lactate dehydrogenase), dithiothreitol, KH2PO4, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), L-glutamate, DL-malate, rotenone (Rot), succinate, atractyloside, antimycin A, N,N,N,N-tetramethyl-p-phenylenediamine (TMPD), ascorbate, ethylenediaminetetraacetic acid (EDTA), glucose, Triton X-100, Tris, phosphoenolpyruvate (PEP), and NADP were obtained from Sigma (St. Louis, MO, United States).

2.3. Determination of Activities of the Respiratory Chain Complexes

Mice received 5 units/g b.wt. of heparin intraperitoneally and were killed by cervical dislocation. The heart, m. soleus, and white glycolytic section of the m. rectus femoris were excised and placed into ice-cold saline to ensure rapid cooling and blood removal. Thin muscle bundles from muscles were then excised in ice-cold solution A, which contained 2.77 mM CaK2EGTA, 7.23 mM K2EGTA 7.23 (free calcium concentration 0.1 μM), 6.56 mM MgCl2, 0.5 mM dithiothreitol (DTT), 50 mM potassium 2-(N-morpholino)-ethanesulfonate (K-MES), 20 mM imidazole, 20 mM taurine, 5.3 mM ATP, and 15 mM phosphocreatine, at pH 7.1 adjusted at 4°C. Muscle fibers were separated using sharp-ended needles, leaving only small areas of contact; the fibers were then transferred to vessels filled with solution A, to which an additional 50 μg of saponin per ml was added, and incubated with mild stirring for 30 min at 4°C for complete solubilization of the sarcolemma. Skinned (permeabilized) fibers were washed three times in solution B, which contained 0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lactobionate, 20 mM taurine, 3 mM KH2PO4, 20 mM HEPES, 110 mM sucrose, and 5 mM pyruvate, and 1 mg/ml bovine serum albumin (BSA) and was set at pH 7.1 (adjusted at 25°C) for 10 min at 4°C by stirring to completely remove all metabolites, particularly trace amounts of ADP.

The activities of the mitochondrial respiratory chain segments in permeabilized muscle fibers were assessed using the polarographic method (Oroboros, Innsbruck, Austria) as respiration rates (VO2) in solution B with 10 mM pyruvate or glutamate, 2 mM malate, and 0.2 μM free Ca2+ at 25°C. Following registration of mitochondrial respiration under nonphosphorylating conditions (basal respiration rate []) in the oxygraph chamber, 2 mM ADP was added to monitor the maximum rate of NADH-linked ADP-dependent respiration; subsequently, complex I was inhibited by 10 μM of rotenone (Rot). Then, 10 mM succinate was added to activate respiratory chain complex II-dependent respiration, 0.1 mM atractyloside (Atr) was added to assess respiratory control by adenine nucleotide translocase (ANT), 10 μM antimycin A was added to inhibit complex III and thereby block the electron flow from complex II to cytochrome c, and 0.5 mM tetramethylphenylene diamine (TMPD) with 2 mM ascorbate was added to activate cytochrome oxidase (COX). Activation of COX in the case of blocked oxidative phosphorylation (OXPHOS) in the presence of Atr was possible due to the smaller number of protons pumped by the respiratory chain per oxygen consumed [32]. In this case, the proton leak in the presence of TMPD was no longer a limiting factor for the respiratory chain. Finally, 5 mM sodium azide (NaN3) was added to inhibit COX. Antimycin-sensitive respiration in the presence of atractyloside () was considered to represent the proton leak. The NaN3-sensitive portion of respiration with TMPD and ascorbate () exhibits COX-related respiration.

2.4. Gene Expression Study

The rectus femoris muscles used in the gene expression analysis were suspended in RNAlater RNA Stabilization Reagent (Qiagen, Düsseldorf, Germany). Total RNA was isolated using the RNeasy Mini Kit (Qiagen). Genomic DNA wipeout and reverse transcription were performed with QuantiTect® Reverse Transcription Kit (Qiagen), in accordance with the manufacturer’s instructions (QuantiTect® Reverse Transcription Handbook, 2005). A QuantiTect SYBR Green PCR Kit (Qiagen, Düsseldorf, Germany) was used to perform real-time PCR amplification with mouse gene-specific primers (Table 1). Fluorescence data during PCR was collected with a StepOnePlus™ Real-Time PCR Instrument (Applied Biosystems, Foster City, CA, United States) and an intercalator-based approach (also known as the SYBR Green method). The comparative threshold cycle (ΔCT, ΔΔCT) technique was used to determine the relative target quantities in samples [33], with all measurements normalized to the endogenous control gene ACTB. Relative target quantity in each sample was assessed by comparing normalized target quantity in each sample to normalized target quantity in the reference sample.


PrimerSequence 5 > 3

UCP2F: GCTGGTGGTGGTCGGAGAT
R: TGAAGTGGCAAGGGAGG
UCP3F: GCTGACACGAGAAACTGAACTAAA
R: GGAGTTGACTCTGGTTTTCTTTGT
ACTBF: AGCCATGTACGTAGCCATCCA
R: GACTTTGCTTTCCTTGGTCAGG

F: forward; R: reverse.
2.5. Determination of Enzymatic Activities

The heart muscle, m. soleus, and the glycolytic part of m. rectus femoris were frozen in liquid nitrogen and stored at −80°C; these muscle tissues were later allowed to thaw at 0°C and homogenized by sonication (Bandelin Sonopuls HD 2200, probe MS 72, Sigma-Aldrich, St. Louis, MO, United States) on ice for 15 s in a medium containing 1 mM EDTA, 1 mM DTT, 10 mM glucose, 5 mM MgCl2, and 5 mM HEPES, at pH 8 (maintained by NaOH), with 0.1% Triton X-100 and 5 mg/ml leupeptin added to the mixture. After homogenization, the probe was kept on ice for an additional 30 s. The homogenization cycle was repeated twice thereafter, and the homogenates were left on ice for 1 h to allow complete extraction of the enzymes. Measurement of pyruvate kinase (PK) activity was performed using a spectrophotometric cuvette under stirring conditions in solution containing 26.7 mM KHPO4 26.7 (pH 7.6, 37°C), 6.67 mM MgSO4, 0.24 mM NADH, 0.5 mM PEP, 3 mM ADP, and 10 IU/ml lactate dehydrogenase (LDH). After baseline registration, the reaction was initiated with the addition of the homogenate, and PK activity was derived from subsequent changes in NADH oxidation rates at 340 nm. Measurement of citrate synthase (CS) activity was performed using a Citrate Synthase Assay Kit (Sigma-Aldrich, St. Louis, MO, United States).

2.6. Proteomics Sample Preparation

Protein content of the homogenates was determined by precipitation with a methanol : chloroform : water solution in a 2 : 1 : 3 ratio, respectively, and suspended in digestion buffer (7 M thiourea, 2 M urea, and 100 mM ammonium bicarbonate). After reduction with 2.5 mM dithiothreitol and alkylation with 5 mM chloroacetamide, the samples were first predigested with 1 : 50 (protease : protein ratio) Lys-C (Wako Pure Chemical Industries, Osaka, Japan) for 4 h, diluted 5-fold with 100 mM ammonium bicarbonate, and then digested for 16 h with 1 : 50 trypsin at room temperature. Peptides were desalted using C18 (3M, Maplewood, Minnesota, United States) StageTips and reconstituted in 0.5% trifluoroacetic acid.

2.7. LC/MS/MS Analysis

Injected peptides were separated on an Ultimate 3000 RSLCnano system (Dionex, Sunnyvale, California, United States) using a C18 cartridge trap column (Dionex) in backflush configuration and an in-house packed (3 μm C18 particles, Dr. Maisch GmbH, Ammerbuch, Germany) analytical 50 cm × 75 μm emitter column (New Objective Inc., Woburn, MA, United States). Peptides were eluted at 200 nl/min with a 5–35% B 180 min gradient (buffer B: 80% acetonitrile + 0.1% formic acid, buffer A: 0.1% formic acid) to a Q Exactive Plus (Thermo Fisher Scientific, Waltham, MA, United States) tandem mass spectrometer operating with a top 10 strategy. Briefly, one 350–1400 m/z MS scan at a resolution of was followed by higher energy collisional dissociation fragmentation (normalized collision energy of 26) of the 10 most intense ions (charge states +2 to +6) at . MS and MS/MS ion target values were and , respectively, and injection times were limited to 50 ms. Dynamic exclusion was set to 50 s.

2.8. Proteomics Data Analysis

Mass spectrometric raw data were processed with MaxQuant 1.5.3.17 software [34]. Label-free quantification with the MaxQuant LFQ algorithm [35] was enabled with default settings with the exception of the minimal ratio count (number of peptides quantified to report a protein quantification), which was set to 1 peptide. Methionine oxidation and protein N-terminal acetylation were set as variable modifications. Cysteine carbamidomethylation was defined as a fixed modification. Search was performed against the UniProt (http://www.uniprot.org) Mus musculus reference proteome database (downloaded on 11 November 2015; 57,320 entries) using the tryptic digestion rule Trypsin/P. Only identifications minimally 1 peptide 7 amino acids long were accepted, and transfer of identifications between runs was enabled. Peptide-spectrum match and protein false discovery rate (FDR) were kept below 1% using a target-decoy approach. All other parameters were kept at default settings.

2.9. Statistical Analysis

All statistical analyses were performed with Student’s -test, and data are presented as mean ± SEM, with significance set at .

3. Results

3.1. Anatomical Data of Wfs1-Deficient and Wild-Type Mice

Body weights and muscle weights of Wfs1-deficient mice were significantly reduced compared to wild-type mice (Table 2); however, the heart-to-body weight and soleus muscle-to-body weight ratios were similar in both mice, suggesting that the absence of wolframin was not associated with atrophy of these muscles. In contrast, the quadriceps femoris muscle-to-body weight ratio was significantly reduced, indicating atrophy of this muscle and in part of the m. rectus femoris.


CharacteristicWT ()Wfs1KO ()

Body weight (g)30.9 ± 1.119.9 ± 1.2
Heart weight (mg)161.5 ± 8.3113.4 ± 7.6
Heart/body weight ratio (mg/g)5.59 ± 0.346.05 ± 0.06
Soleus muscle weight (mg)5.47 ± 0.284.50 ± 0.41
Soleus muscle/body weight ratio (mg/g)0.189 ± 0.0060.235 ± 0.020
Quadriceps femoris muscle weight (mg)196.7 ± 5.93100.3 ± 3.62
Quadriceps femoris muscle/body weight ratio (mg/g)6.05 ± 0.094.82 ± 0.27

Means ± SEM are shown. Compared to wild type: , , and .
3.2. Mitochondrial Respiration in Muscles of Wfs1-Deficient Mice

The function of different respiratory chain complexes in the muscle fibers of saponin-skinned wild-type and Wfs1-deficient mice was assessed using a substrate/inhibitor titration protocol [36, 37] (Figure 1(a)). Mitochondrial respiration in the permeabilized muscle fibers increased over the basal levels following the addition of ADP, indicating a coupling of complex I-dependent respiration to ADP phosphorylation. After registration of respiration in the presence of ADP (Figure 1(a)), rotenone was added to inhibit complex I, and succinate was subsequently added to stimulate complex II-dependent respiration. Next, atractyloside was added, which strongly reduces succinate-dependent respiration; this was suppressed even further by the addition of 10 μM antimycin A, which inhibits the electron flow from complex III to cytochrome c in mitochondria. Cytochrome c oxidase was activated with TMPD and ascorbate and then suppressed by NaN3 (Figure 1(a)). As previous experiments have shown, VNaN3 remains higher than V0 [38, 39], a background respiration caused by strong autooxidation of TMPD [40]. We found that the basal respiration rate (V0) was 2.59 times () greater in Wfs1-deficient m. rectus femoris (Figure 1(d), Table S1) than in wild-type m. rectus femoris, whereas there were no differences in the heart and m. soleus between the two mice (Figures 1(b) and 1(c)). After the addition of ADP into the medium of wild-type m. rectus femoris, the rate of respiration increased to 1.06 ± 0.10 nmol O2/min/mg w.w. (Figure 1(d), Table S1), a rate lower than that of the corresponding increases in the other muscles. However, for the respiratory control index, the relative increase of 10.6 times with respect to V0 for the wild-type m. rectus femoris was greater than that for the other muscles (Table S1). The corresponding relative increase of the respiration rate for the Wfs1-deficient m. rectus femoris was only 4.87 times, which was lower than in the m. soleus and practically the same as in the heart. Musculus rectus femoris VADP was 40% higher in Wfs1-deficient mice than in wild-type mice () (Figure 1(d)) but was 34% lower in Wfs1-deficient m. soleus than in wild-type m. soleus () (Figure 1(c)). In addition, ADP- and complex II-dependent respirations were 62% higher in Wfs1-deficient m. rectus femoris (), whereas Wfs1-deficient m. soleus was 24% lower than in wild-type m. soleus (). Blocked OXPHOS (Atr) respiration was 75% higher in Wfs1-deficient m. rectus femoris than in wild-type m. rectus femoris (). The difference between VAtr and VAnt, as proton leak-dependent respiration, was 73% greater in Wfs1-deficient m. rectus femoris than in wild-type m. rectus femoris (), and complex IV-dependent respiration (VCOX) was greater by 31% in Wfs1-deficient m. rectus femoris. There were no significant differences in complex I and OXPHOS-related oxygen flux (VADP-V0) between wild-type and Wfs1-deficient m. rectus femoris (0.936 ± 0.08 and 1.171 ± 0.10 nmol O2/min/mg w.w., respectively).

3.3. Quantitative Real-Time RT-PCR Data Analysis

It is possible that the greater basal respiration (V0) and differences in VAtr and VAnt in Wfs1-deficient m. rectus femoris compared to wild-type m. rectus femoris that we observed in the respiratory experiments were caused by increased proton leak in this muscle. Proton leak in skeletal muscles depends on uncoupler protein levels, and thus, we examined UCP2 and UCP3 expressions at the genetic level. We found that, relative to the housekeeping gene ACTB, UCP2 mRNA levels were 1.05 ± 0.37 in wild-type m. rectus femoris and 2.75 ± 0.30 in Wfs1-deficient m. rectus femoris, a difference of 2.6 times (). UCP3 expression was an order of magnitude lower than that of UCP2 and did not differ among the muscle types (Figure 2).

3.4. Enzymatic Activity

Citrate synthase activity was 77.0 ± 10.0 in wild-type heart muscles, but activity of this enzyme was 7.5 times lower (10.3 ± 1.1) in the m. soleus and 2 times lower still (4.4 ± 0.9) in the m. rectus femoris than in the m. soleus (Figure 3(a)). Compared with controls, there was no change in citrate synthase activity levels in Wfs1-deficient heart and m. soleus fibers, but activity levels were 1.46-fold () higher in the Wfs1-deficient m. rectus femoris. Pyruvate kinase activity levels did not differ between wild-type and Wfs1-deficient muscles (Figure 3(b)).

3.5. Proteomics of Mitochondrial Proteins

We performed an LC/MS/MS analysis to confirm the results obtained from the oxygraphic experiments. Twenty-seven subunits of respiratory chain complex I were identified. In wild-type mice, protein amounts were determined to be ~5 times higher in the m. soleus than in the m. rectus femoris and ~5 times higher in the heart muscle than in the m. soleus (Figure S1). Amounts of typical representatives of the complex I proteins NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 (Ndufa2) and NADH dehydrogenase [ubiquinone] iron-sulfur protein 3 (Ndufs3) are shown in Figure 4. Respiratory chain complex II or succinate dehydrogenase is composed of four subunits consisting of the succinate dehydrogenase [ubiquinone] flavoprotein subunit SDHA, iron-sulfur protein SDHB, cytochrome b560 subunit SDHC, and cytochrome b small subunit SDHD. This enzyme plays a role in both the citric acid cycle and the respiratory chain. Our LC/MS/MS analysis revealed the same increases (2.08 times) in both hydrophilic subunits SDHA and SDHB in Wfs1-deficient m. rectus femoris compared to wild-type m. rectus femoris and that the amounts of two hydrophobic subunits of succinate dehydrogenase, SDHC and SDHD, were more than an order of magnitude lower and did not differ significantly between wild-type and Wfs1-deficient muscles (Figure S4). Amounts of complex II protein and succinate dehydrogenase [ubiquinone] iron-sulfur subunit in wild-type and Wfs1-deficient mice muscles are shown in Figure 4. Eight components of the ubiquinol-cytochrome c reductase complex (complex III) were identified in Wfs1-deficient m. rectus femoris, of which amounts of six components were significantly higher by ~1.5 times (Figure S2). Similar results were obtained for respiratory chain complex IV, for which protein amounts were significantly higher in Wfs1-deficient m. rectus femoris than in wild-type m. rectus femoris (Figure S2). Amounts of typical representatives of complex IV are shown in Figure 4. Mitochondrial membrane ATP synthase (F1F0 ATP synthase or complex V) consists of two structural domains, subunits alpha (Atp5a1) and beta (Atp5b), which form the catalytic core in the F1 domain, which were compared to other subunits of F1F0 ATP synthase, and which are most abundant in muscle homogenates (Figure S3). The amounts of these subunits are shown in Figure 4. Abundance of subunit alpha Atp5a1 was 1.81 times () and that of subunit beta 1.58 times () higher in Wfs1-deficient m. rectus femoris than in wild-type m. rectus femoris. In the homogenates, H+ transporting delta subunit of F1 domain Atp5d; ATP synthase subunit gamma Atp5c1 of the central stalk; and several subunits of ATP synthase F0 domain, namely, d Atp5h, e Atp5i, f Atp5j2, g Atp5l, o Atp5o, and ATP synthase-coupling factor 6 Atp5j, were also all detected at moderate levels. The amounts of all these subunits were higher in the m. rectus femoris of Wfs1-deficient mice than in that of wild-type mice (Figure S3).

The citric acid cycle is also an important mitochondrial enzymatic system that provides electrons to the respiratory chain. Citrate synthase, the first step of the citric acid cycle, is commonly used as a quantitative enzyme marker for the mitochondrial presence. As with enzyme activity, higher amounts of citrate synthase were present in Wfs1-deficient m. rectus femoris compared to wild-type m. rectus femoris (by 1.62 times, , Figure 5), as was also found for aconitate hydratase Aco2 (by 1.71 times, ), isocitrate dehydrogenase [NAD] subunit gamma Idh3g (by 1.86 times, ), 2-oxoglutarate dehydrogenase Ogdh (by 1.42 times, ), succinyl-CoA ligase subunit beta (Sucla2) (by 1.42 times, ), and mitochondrial malate dehydrogenase (by 1.93 times, ) (Figure S4). Concentrations of pyruvate dehydrogenase, an enzyme closely linked to the citrate cycle, were also increased in Wfs1-deficient m. rectus femoris compared to wild-type m. rectus femoris, with pyruvate dehydrogenase E1 component subunit alpha 1.69 times () and subunit beta 1.56 times () higher. Beta-oxidation of fatty acids takes place in the mitochondria, and all enzymes involved in beta-oxidation that were identified in our LC/MS/MS analysis were also significantly higher (1.7–3.3 times, ) in Wfs1-deficient m. rectus femoris than in wild-type m. rectus femoris (Figure S5). Amounts of the typical representative medium-chain-specific acyl-CoA dehydrogenase (Acadm) and hydroxyacyl-coenzyme A dehydrogenase (Hadh) are also shown in Figure 5.

3.6. Amounts of Indicators of Metabolic Profile and Regulators of Mitochondrial Function

Sirtuins are a class of proteins of relatively small molecular mass; these proteins have deacylase activity and regulate important biological pathways [41]. Mitochondrial sirtuin 3 and sirtuin 5 amounts were 6.24 and 1.68 times higher, respectively, in Wfs1-deficient m. rectus femoris than in wild-type m. rectus femoris (Table 3), and sirtuin 5 was considerably more abundant than sirtuin 3 in all muscles. Amounts of cytoplasmic sirtuin 2 were lower than those of mitochondrial sirtuins in oxidative muscles. Both parvalbumin, a calcium-binding albumin protein, and sarcoplasmic reticulum calcium ATPase are normally found in greater quantities in fast-contracting glycolytic muscles. Parvalbumin alpha and sarcoplasmic reticulum calcium ATPase were 2.15 () and 1.89 () times lower, respectively, in Wfs1-deficient m. rectus femoris than in wild-type m. rectus femoris (Table 3). Moreover, compared to the wild type, the abundance of some glycolytic enzymes was also lower in Wfs1-deficient m. rectus femoris; for instance, fructose-bisphosphate aldolase (Aldoa), alpha-enolase (Eno1), and L-lactate dehydrogenase A chain (Ldha) were reduced by 25% (), by 27% (), and by 33% (), respectively, in the m. rectus femoris of Wfs1-deficient mice relative to that of wild-type mice (Figure S6).


ProteinsGenesM. rectus femorisM. soleusHeart
Wfs1+/+ Wfs1−/− Wfs1+/+ Wfs1−/− Wfs1+/+ Wfs1−/−

NAD-dependent protein deacylase sirtuin-5, mitochondrialSirt5 ±  ±  ±  ±  ±  ± 
NAD-dependent protein deacetylase sirtuin-3Sirt3 ±  ±  ±  ±  ±  ± 
NAD-dependent protein deacetylase sirtuin-2Sirt2 ±  ±  ±  ±  ±  ± 
Parvalbumin alphaPvalb ±  ± 0 ±  ±  ± 0.00
Sarcoplasmic/endoplasmic reticulum calcium ATPaseAtp2a ±  ±  ±  ±  ±  ± 

Values are means ± SEM; n = the number of specimens studied. Compared to wild type: , , and .

4. Discussion

To the best of our knowledge, this represents the first study in which the mitochondrial function and abundance of mitochondrial proteins in the muscles of Wfs1-deficient mice were characterized. Surprisingly, we found that, compared to the wild type, the amounts of the majority of mitochondrial proteins and activity levels of citrate synthase were significantly higher in Wfs1-deficient glycolytic muscle tissues (~1.5-fold). ADP-dependent respiration with complex I and II substrates was also higher in Wfs1-deficient m. rectus femoris than in wild-type m. rectus femoris, and complex IV-dependent respiration was one-third greater in this muscle in Wfs1-deficient mice than in wild-type mice (Figure 1(d)). As can be seen in Table 2, the quadriceps muscle-to-body weight ratio was lower in Wfs1-deficient mice. Similarly, STZ-induced type I diabetes produces profound atrophy of fast-twitch muscles and especially the fast glycolytic (FG) fibers [4246]. Atrophy of glycolytic muscle fibers in our model mice most likely caused even higher rates of respiration and mitochondrial protein abundance in the Wfs1-deficient glycolytic rectus femoris muscle. Comparable results were reported from recent work, in which it was shown that basal oxygen consumption (measured at the whole-organism level) was 1.3 times higher in Wfs1-deficient mice, and heat production was also 1.3 times higher in Wfs1-deficient mice [47]. Transient receptor potential melastatin 8 (TRPM8) channels, which are activated by cold (8–28°C) and by some chemicals like menthol, are key pathways for heat production signaling [4850]. Dietary menthol was shown to significantly increase oxygen consumption in WT mice but not in TRMP8KO mice, suggesting that dietary menthol increases the resting metabolic rate via TRPM8 activation [51]. Likewise, RNA sequencing analysis revealed increased expression of TRMP8 in the hippocampus of Wfs1-deficient mice, and metabolic studies have shown higher response to menthol administration in Wsf1-deficient mice compared to WT mice. Overexpressed TRMP8 in Wfs1-deficient mice might be the reason for the higher basal oxygen consumption and heat production in this type compared to WT mice [47]. Given that TRMP8-dependent thermogenesis is caused by activation of uncoupler protein 1 (UCP1) in brown adipose tissue [51], the enhanced heat production and oxygen consumption of Wfs1-deficient mice may be due to increased mitochondrial proton leak in BAT, but the results of our study suggest that elevated mitochondrial proton leak also occurs in the glycolytic muscle rectus femoris. Compared to the wild type, basal respiration without ADP was 2.5-folds higher and proton leak-dependent respiration 1.7-folds higher in Wfs1-deficient muscles. OXPHOS-related oxygen flux (VADP-V0) did not differ significantly between wild-type and Wfs1-deficient m. rectus femoris muscles; thus, in the latter, the proportion of proton leak to OXPHOS was increased, and accordingly, the respiratory control index was 2 times lower in Wfs1-deficient m. rectus femoris. Increases in the relative proportion of proton leak in glycolytic skeletal muscle may depend on higher levels of UCP2, as we observed an increase in RNA levels of this protein; however, LC/MS/MS analysis failed to detect the presence of UCP2 proteins in any of the muscle types, indicating that increased proton leak simply damages mitochondria in Wfs1-deficient glycolytic muscles and that the increase in mitochondrial proteins is most likely compensating for decreasing mitochondrial quality. It has been shown that SIRT3 stimulates mitochondrial biogenesis [5254], and thus, the higher levels of mitochondrial sirtuin 3 in Wfs1-deficient m. rectus femoris compared to wild-type m. rectus femoris likely stimulate mitochondrial biogenesis in this tissue. Concentrations of sirtuin 5 were also higher in Wfs1-deficient m. rectus femoris; like other sirtuins, sirtuin 5 has deacylase activity and is capable of removing acetyl, succinyl, and malonyl groups from the lysine residues of proteins, but in contrast to sirtuin 3, it does not seem to be involved in mitochondrial biogenesis [55, 56]. Levels of cytoplasmic sirtuin 2 were roughly the same in Wfs1-deficient and wild-type m. rectus femoris, which may simply reflect a reduction in the amount of cytoplasm relative to mitochondria as levels of mitochondrial sirtuins and other mitochondrial proteins increased.

In contrast to glycolytic rectus femoris, either there were no changes in the oxidative muscles of Wfs1-deficient mice or changes occurred in the opposite direction. In the heart muscle, for instance, mitochondrial protein abundance, citrate synthase activity, and mitochondrial respiration remained unchanged, and compared to the wild type, ADP-dependent respiration involving both complex I and complex II substrates was lower in Wfs1-deficient m. soleus. Furthermore, although we observed downward trends in the parameters of several mitochondrial proteins in Wfs1-deficient m. soleus, the amounts of other proteins and the activity level of citrate synthase did not change.

The Wfs1 protein interacts with sarco/endoplasmic reticulum ATPase (Atp2a) and negatively regulates Atp2a turnover, possibly via proteasome-mediated degradation. In Wfs1-depleted cells, Wfs1–Atp2a interaction is limited, and therefore, the amount of Atp2a is upregulated [57]; however, we did not observe higher levels of Atp2a in Wfs1-deficient muscles. In fact, Atp2a was lower in Wfs1-deficient m. rectus femoris than in wild-type m. rectus femoris, as was parvalbumin alpha (Pvalb), a protein involved in calcium signaling. Concentrations of parvalbumin are normally high in fast-contracting muscles and low in slow-contracting muscles [58], whereas slow-twitch muscles generally contain more mitochondria and less cytoplasm. We also found that, compared to the wild type, concentrations of some glycolytic enzymes were lower in Wfs1-deficient m. rectus femoris. As such, the reduced amounts of Atp2a1 and Pvalb may indicate a shift from fast-contracting glycolytic m. rectus femoris to slower oxidative muscles in Wfs1-deficient mice. Like type 1 diabetes, this shift in the glycolytic muscle type is probably triggered by insulin deficiency and the atrophy of FG fibers in Wsf1-deficient mice and missed in oxidative muscles [45, 46]. Increased relative proton leak, which reduces the efficiency of ATP synthesis, is another alteration in m. rectus femoris metabolism. It is possible that these same pathologies occur in patients suffering from WS; considering the high percentage of glycolytic muscles in the human body, such changes may be major causes of the chronic progressive fatigue and other muscle disorders experienced by WS patients [9].

5. Conclusions

Mitochondrial protein concentrations, citrate synthase activity, and mitochondrial respiration of permeabilized fibers were found to be significantly elevated in Wfs1-deficient m. rectus femoris. Compared to the wild type, efficiency of ATP synthesis declined in the mitochondria of Wfs1-deficient m. rectus femoris muscle due to higher proton leak-dependent respiration, whereas there was no difference in OXPHOS-dependent respiration.

Data Availability

The mass spectrometry proteomics data used to support the findings of this study have been deposited to the ProteomeXchange Consortium via the PRIDE [59] partner repository with the dataset identifier PXD011019 and will be published as data article [60]. The other data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no competing interests.

Acknowledgments

The authors thank Ellen Gvozdkova and Martin Eimre for technical assistance. This work was supported by the European Union’s Horizon 2020 research and innovation programme TRANSGENO project under grant agreement No. 668989 and Institutional Research Funding IUT20-46 of the Haridus- ja Teadusministeerium.

Supplementary Materials

Table S1: rates of mitochondrial respiration. Figure S1: amounts of respiratory chain complex I subunits. Figure S2: amounts of respiratory chain complex III and IV subunits. Figure S3: amounts of respiratory chain complex V subunits. Figure S4: amounts of citrate cycle enzymes and their subunits. Figure S5: amounts of fatty acid beta-oxidation enzymes. Figure S6: amounts of glycolytic enzymes. (Supplementary Materials)

References

  1. S. Hofmann, C. Philbrook, K. D. Gerbitz, and M. F. Bauer, “Wolfram syndrome: structural and functional analyses of mutant and wild-type wolframin, the WFS1 gene product,” Human Molecular Genetics, vol. 12, no. 16, pp. 2003–2012, 2003. View at: Publisher Site | Google Scholar
  2. H. Inoue, Y. Tanizawa, J. Wasson et al., “A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome),” Nature Genetics, vol. 20, no. 2, pp. 143–148, 1998. View at: Publisher Site | Google Scholar
  3. A. C. Riggs, E. Bernal-Mizrachi, M. Ohsugi et al., “Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis,” Diabetologia, vol. 48, no. 11, pp. 2313–2321, 2005. View at: Publisher Site | Google Scholar
  4. D. Takei, H. Ishihara, S. Yamaguchi et al., “WFS1 protein modulates the free Ca(2+) concentration in the endoplasmic reticulum,” FEBS Letters, vol. 580, no. 24, pp. 5635–5640, 2006. View at: Publisher Site | Google Scholar
  5. T. M. Strom, K. Hörtnagel, S. Hofmann et al., “Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein,” Human Molecular Genetics, vol. 7, no. 13, pp. 2021–2028, 1998. View at: Publisher Site | Google Scholar
  6. E. Simsek, T. Simsek, S. Tekgül, S. Hosal, V. Seyrantepe, and G. Aktan, “Wolfram (DIDMOAD) syndrome: a multidisciplinary clinical study in nine Turkish patients and review of the literature,” Acta Paediatrica, vol. 92, no. 1, pp. 55–61, 2003. View at: Google Scholar
  7. R. Medlej, J. Wasson, P. Baz et al., “Diabetes mellitus and optic atrophy: a study of Wolfram syndrome in the Lebanese population,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 4, pp. 1656–1661, 2004. View at: Publisher Site | Google Scholar
  8. M. A. Ganie, B. A. Laway, S. Nisar et al., “Presentation and clinical course of Wolfram (DIDMOAD) syndrome from North India,” Diabetic Medicine, vol. 28, no. 11, pp. 1337–1342, 2011. View at: Publisher Site | Google Scholar
  9. Diabetes UK, “Wolfram syndrome,” https://www.diabetes.org.uk/diabetes-the-basics/other-types-of-diabetes/wolfram-syndrome. View at: Google Scholar
  10. Genetics Home Reference, “Wolfram syndrome,” 2012, http://ghr.nlm.nih.gov/condition/wolfram-syndrome. View at: Google Scholar
  11. The Genetic and Rare Diseases Information Center, “Wolfram syndrome,” 2018, https://rarediseases.info.nih.gov/diseases/7898/wolfram-syndrome#ref_7125. View at: Google Scholar
  12. H. Ishihara, S. Takeda, A. Tamura et al., “Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion,” Human Molecular Genetics, vol. 13, no. 11, pp. 1159–1170, 2004. View at: Publisher Site | Google Scholar
  13. T. G. Barrett and S. E. Bundey, “Wolfram (DIDMOAD) syndrome,” Journal of Medical Genetics, vol. 34, no. 10, pp. 838–841, 1997. View at: Publisher Site | Google Scholar
  14. C. J. Smith, P. A. Crock, B. R. King, C. J. Meldrum, and R. J. Scott, “Phenotype-genotype correlations in a series of Wolfram syndrome families,” Diabetes Care, vol. 27, no. 8, pp. 2003–2009, 2004. View at: Publisher Site | Google Scholar
  15. J. Rohayem, C. Ehlers, B. Wiedemann et al., “Diabetes and neurodegeneration in Wolfram syndrome: a multicenter study of phenotype and genotype,” Diabetes Care, vol. 34, no. 7, pp. 1503–1510, 2011. View at: Publisher Site | Google Scholar
  16. A. D. Baron, G. Brechtel, P. Wallace, and S. V. Edelman, “Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans,” American Journal of Physiology-Endocrinology and Metabolism, vol. 255, no. 6, pp. E769–E774, 1988. View at: Publisher Site | Google Scholar
  17. P. Nuutila, V. A. Koivisto, J. Knuuti et al., “Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo,” Journal of Clinical Investigation, vol. 89, no. 6, pp. 1767–1774, 1992. View at: Publisher Site | Google Scholar
  18. I. Idris, S. Gray, and R. Donnelly, “Insulin action in skeletal muscle: isozyme-specific effects of protein kinase C,” Annals of the New York Academy of Science, vol. 967, no. 1, pp. 176–182, 2002. View at: Publisher Site | Google Scholar
  19. H. Andersen, S. Nielsen, C. E. Mogensen, and J. Jakobsen, “Muscle strength in type 2 diabetes,” Diabetes, vol. 53, no. 6, pp. 1543–1548, 2004. View at: Publisher Site | Google Scholar
  20. E. Cetinus, M. A. Buyukbese, M. Uzel, H. Ekerbicer, and A. Karaoguz, “Hand grip strength in patients with type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 70, no. 3, pp. 278–286, 2005. View at: Publisher Site | Google Scholar
  21. M. E. Khallaf, E. E. Fayed, and M. I. Al-Rashidi, “Effect of longstanding diabetes mellitus type II on hand grip strength and pinch power of females in the city of Hail-KSA,” IOSR Journal of Nursing and Health Science, vol. 3, no. 1, pp. 41–44, 2014. View at: Publisher Site | Google Scholar
  22. H. Andersen, “Motor dysfunction in diabetes,” Diabetes/Metabolism Research and Reviews, vol. 28, Supplement 1, pp. 89–92, 2012. View at: Publisher Site | Google Scholar
  23. H. Mori, A. Kuroda, M. Araki et al., “Advanced glycation end-products are a risk for muscle weakness in Japanese patients with type 1 diabetes,” Journal of Diabetes Investigation, vol. 8, no. 3, pp. 377–382, 2017. View at: Publisher Site | Google Scholar
  24. A. Barrientos, J. Casademont, A. Saiz et al., “Autosomal recessive Wolfram syndrome associated with an 8.5-kb mtDNA single deletion,” American Journal of Human Genetics, vol. 58, no. 5, pp. 963–970, 1996. View at: Google Scholar
  25. A. Rötig, V. Cormier, P. Chatelain et al., “Deletion of mitochondrial DNA in a case of early-onset diabetes mellitus, optic atrophy, and deafness (Wolfram syndrome, MIM 222300),” Journal of Clinical Investigation, vol. 91, no. 3, pp. 1095–1098, 1993. View at: Publisher Site | Google Scholar
  26. N. Mezghani, M. Mnif, E. Mkaouar-Rebai et al., “The mitochondrial ND1 m.3337G>A mutation associated to multiple mitochondrial DNA deletions in a patient with Wolfram syndrome and cardiomyopathy,” Biochemical and Biophysical Research Communications, vol. 411, no. 2, pp. 247–252, 2011. View at: Publisher Site | Google Scholar
  27. M. J. Jackson, L. A. Bindoff, K. Weber et al., “Biochemical and molecular studies of mitochondrial function in diabetes insipidus, diabetes mellitus, optic atrophy, and deafness,” Diabetes Care, vol. 17, no. 7, pp. 728–733, 1994. View at: Publisher Site | Google Scholar
  28. T. G. Barrett, M. Scott-Brown, A. Seller, A. Bednarz, K. Poulton, and J. Poulton, “The mitochondrial genome in Wolfram syndrome,” Journal of Medical Genetics, vol. 37, no. 6, pp. 463–466, 2000. View at: Publisher Site | Google Scholar
  29. S. Kõks, U. Soomets, J. L. Paya-Cano et al., “Wfs1 gene deletion causes growth retardation in mice and interferes with the growth hormone pathway,” Physiological Genomics, vol. 37, no. 3, pp. 249–259, 2009. View at: Publisher Site | Google Scholar
  30. K. Noormets, S. Kõks, M. Muldmaa, L. Mauring, E. Vasar, and V. Tillmann, “Sex differences in the development of diabetes in mice with deleted wolframin (Wfs1) gene,” Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 5, pp. 271–275, 2011. View at: Publisher Site | Google Scholar
  31. H. Luuk, S. Kõks, M. Plaas, J. Hannibal, J. F. Rehfeld, and E. Vasar, “Distribution of Wfs1 protein in the central nervous system of the mouse and its relation to clinical symptoms of the Wolfram syndrome,” Journal of Comparative Neurology, vol. 509, no. 6, pp. 642–660, 2008. View at: Publisher Site | Google Scholar
  32. S. Papa, N. Capitanio, G. Capitanio, E. De Nitto, and M. Minuto, “The cytochrome chain of mitochondria exhibits variable H+/e stoichiometry,” FEBS Letters, vol. 288, no. 1-2, pp. 183–186, 1991. View at: Publisher Site | Google Scholar
  33. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at: Publisher Site | Google Scholar
  34. J. Cox and M. Mann, “MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification,” Nature Biotechnology, vol. 26, no. 12, pp. 1367–1372, 2008. View at: Publisher Site | Google Scholar
  35. J. Cox, M. Y. Hein, C. A. Luber, I. Paron, N. Nagaraj, and M. Mann, “Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ,” Molecular and Cellular Proteomics, vol. 13, no. 9, pp. 2513–2526, 2014. View at: Publisher Site | Google Scholar
  36. W. Sperl, D. Skladal, E. Gnaiger et al., “High resolution respirometry of permeabilized skeletal muscle fibers in the diagnosis of neuromuscular disorders,” in Detection of Mitochondrial Diseases, F. N. Gellerich and S. Zierz, Eds., vol. 21 of Developments in Molecular and Cellular Biochemistry, pp. 71–78, Springer, Boston, MA, USA, 1997. View at: Publisher Site | Google Scholar
  37. T. Regueira, P. M. Lepper, S. Brandt et al., “Hypoxia inducible factor-1 alpha induction by tumour necrosis factor-alpha, but not by toll-like receptor agonists, modulates cellular respiration in cultured human hepatocytes,” Liver International, vol. 29, no. 10, pp. 1582–1592, 2009. View at: Publisher Site | Google Scholar
  38. M. Roosimaa, T. Põdramägi, L. Kadaja et al., “Dilation of human atria: increased diffusion restrictions for ADP, overexpression of hexokinase 2 and its coupling to oxidative phosphorylation in cardiomyocytes,” Mitochondrion, vol. 13, no. 5, pp. 399–409, 2013. View at: Publisher Site | Google Scholar
  39. R. Pääsuke, M. Eimre, A. Piirsoo et al., “Proliferation of human primary myoblasts is associated with altered energy metabolism in dependence on ageing in vivo and in vitro,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 8296150, 10 pages, 2016. View at: Publisher Site | Google Scholar
  40. R. Munday, “Generation of superoxide radical, hydrogen peroxide and hydroxyl radical during the autoxidation of N,N,N,N-tetramethyl-p-phenylenediamine,” Chemico-Biological Interactions, vol. 65, no. 2, pp. 133–143, 1988. View at: Publisher Site | Google Scholar
  41. H. Yamamoto, K. Schoonjans, and J. Auwerx, “Sirtuin functions in health and disease,” Molecular Endocrinology, vol. 21, no. 8, pp. 1745–1755, 2007. View at: Publisher Site | Google Scholar
  42. R. B. Armstrong, P. D. Gollnick, and C. D. Ianuzzo, “Histochemical properties of skeletal muscle fibers in streptozotocin-diabetic rats,” Cell and Tissue Research, vol. 162, no. 3, pp. 387–394, 1975. View at: Publisher Site | Google Scholar
  43. M. Cotter, N. E. Cameron, D. R. Lean, and S. Robertson, “Effects of long-term streptozotocin diabetes on the contractile and histochemical properties of rat muscles,” Quarterly Journal of Experimental Physiology, vol. 74, no. 1, pp. 65–74, 1989. View at: Publisher Site | Google Scholar
  44. M. Medina-Sanchez, C. Rodriguez-Sanchez, J. A. Vega-Alvarez, A. Menedez-Pelaez, and A. Perez-Casas, “Proximal skeletal muscle alterations in streptozotocin-diabetic rats: a histochemical and morphometric analysis,” American Journal of Anatomy, vol. 191, no. 1, pp. 48–56, 1991. View at: Publisher Site | Google Scholar
  45. K. M. Klueber and J. D. Feczko, “Ultrastructural, histochemical, and morphometric analysis of skeletal muscle in a murine model of type I diabetes,” The Anatomical Record, vol. 239, no. 1, pp. 18–34, 1994. View at: Publisher Site | Google Scholar
  46. A. A. Aughsteen, A. M. Khair, and A. A. Suleiman, “Quantitative morphometric study of the skeletal muscles of normal and streptozotocin-diabetic rats,” Journal of the Pancreas, vol. 10, no. 4, pp. 382–389, 2006. View at: Google Scholar
  47. M. Ehrlich, M. Ivask, A. Raasmaja, and S. Kõks, “Analysis of metabolic effects of menthol on WFS1-deficient mice,” Physiological Reports, vol. 4, no. 1, article e12660, 2016. View at: Publisher Site | Google Scholar
  48. D. D. McKemy, W. M. Neuhausser, and D. Julius, “Identification of a cold receptor reveals a general role for TRP channels in thermosensation,” Nature, vol. 416, no. 6876, pp. 52–58, 2002. View at: Publisher Site | Google Scholar
  49. A. M. Peier, A. Moqrich, A. C. Hergarden et al., “A TRP channel that senses cold stimuli and menthol,” Cell, vol. 108, no. 5, pp. 705–715, 2002. View at: Publisher Site | Google Scholar
  50. R. V. Olsen, H. H. Andersen, H. G. Møller, P. W. Eskelund, and L. Arendt-Nielsen, “Somatosensory and vasomotor manifestations of individual and combined stimulation of TRPM8 and TRPA1 using topical L-menthol and trans-cinnamaldehyde in healthy volunteers,” European Journal of Pain, vol. 18, no. 9, pp. 1333–1342, 2014. View at: Publisher Site | Google Scholar
  51. S. Ma, H. Yu, Z. Zhao et al., “Activation of the cold-sensing TRPM8 channel triggers UCP1-dependent thermogenesis and prevents obesity,” Journal of Molecular Cell Biology, vol. 4, no. 2, pp. 88–96, 2012. View at: Publisher Site | Google Scholar
  52. X. Kong, R. Wang, Y. Xue et al., “Sirtuin 3, a new target of PGC-1α, plays an important role in the suppression of ROS and mitochondrial biogenesis,” PLoS One, vol. 22, no. 5, article e11707, 2010. View at: Publisher Site | Google Scholar
  53. A. Giralt, E. Hondares, J. A. Villena et al., “Peroxisome proliferator-activated receptor-gamma coactivator-1alpha controls transcription of the Sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype,” Journal of Biological Chemistry, vol. 286, no. 19, pp. 16958–16966, 2011. View at: Publisher Site | Google Scholar
  54. A. Giralt and F. Villarroya, “SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging,” Biochemical Journal, vol. 444, no. 1, pp. 1–10, 2012. View at: Publisher Site | Google Scholar
  55. M. Gertz and C. Steegborn, “Function and regulation of the mitochondrial sirtuin isoform Sirt5 in Mammalia,” Biochimica et Biophysica Acta, vol. 1804, no. 8, pp. 1658–1665, 2010. View at: Publisher Site | Google Scholar
  56. J. Du, Y. Zhou, X. Su et al., “Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase,” Science, vol. 334, no. 6057, pp. 806–809, 2011. View at: Publisher Site | Google Scholar
  57. M. Zatyka, X. G. Da Silva, E. A. Bellomo et al., “Sarco(endo)plasmic reticulum ATPase is a molecular partner of Wolfram syndrome 1 protein, which negatively regulates its expression,” Human Molecular Genetics, vol. 24, no. 3, pp. 814–827, 2015. View at: Publisher Site | Google Scholar
  58. C. W. Heizmann, M. W. Berchtold, and A. M. Rowlerson, “Correlation of parvalbumin concentration with relaxation speed in mammalian muscles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 23, pp. 7243–7247, 1982. View at: Publisher Site | Google Scholar
  59. J. A. Vizcaíno, A. Csordas, N. del-Toro et al., “2016 update of the PRIDE database and its related tools,” Nucleic Acids Research, vol. 44, no. D1, pp. D447–D456, 2016. View at: Publisher Site | Google Scholar
  60. M. Eimre, S. Kasvandik, M. Ivask, and S. Kõks, “Proteomic dataset of wolframin-deficient mouse heart and skeletal muscles,” Data in Brief, vol. 21, pp. 616–619, 2018, submitted. View at: Google Scholar

Copyright © 2018 Margus Eimre et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

938 Views | 307 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.